Health TidingsImmix Reports NXC-201 Shows 89% Complete Response in Amyloidosis Trial Immix Reports NXC-201 Shows 89% Complete Response in Amyloidosis Trial Read Post »
Health TidingsBrogidirsen Five-Year Data Show Maintained Motor Function in DMD Brogidirsen Five-Year Data Show Maintained Motor Function in DMD Read Post »
Health TidingsLUT014 Shows Significant Improvement in EGFR Inhibitor-Induced Acneiform Ra... LUT014 Shows Significant Improvement in EGFR Inhibitor-Induced Acneiform Ra... Read Post »
Health TidingsTrichomylin Reports Pain and Opioid-Reduction Signals in UTOPIA-1 Trichomylin Reports Pain and Opioid-Reduction Signals in UTOPIA-1 Read Post »
Health Tidings Mergers & AcquisitionsRegeneron and Sanofi Expand Immunology Deal to $8B With Four Long-Acting An... Regeneron and Sanofi Expand Immunology Deal to $8B With Four Long-Acting An... Read Post »
Health TidingsFDA and EMA Grant Orphan Drug Designations to Lemiretprocel for Inherited R... FDA and EMA Grant Orphan Drug Designations to Lemiretprocel for Inherited R... Read Post »
Health TidingsOrforglipron Meets Cardiovascular Safety Goal in Phase 3 ACHIEVE-4 Orforglipron Meets Cardiovascular Safety Goal in Phase 3 ACHIEVE-4 Read Post »
Health TidingsHighlight Therapeutics Reports Positive BO-112 Phase 2b Results in BCC Highlight Therapeutics Reports Positive BO-112 Phase 2b Results in BCC Read Post »
Health TidingsEBGLYSS Shows Rapid Improvements in Hand and Foot Atopic Dermatitis EBGLYSS Shows Rapid Improvements in Hand and Foot Atopic Dermatitis Read Post »
Health TidingsIopofosine I 131 Shows 87.5% Response Rate in Waldenström Macroglobulinemi... Iopofosine I 131 Shows 87.5% Response Rate in Waldenström Macroglobulinemi... Read Post »
Health TidingsLilly’s EloraTZP Delivers Up to 23.3% Weight Loss and 2.9% A1C Reduction ... Lilly’s EloraTZP Delivers Up to 23.3% Weight Loss and 2.9% A1C Reduction ... Read Post »
Health TidingsTrappsol Cyclo Shows Benefit in NPC Trial, Misses Statistical Significance Trappsol Cyclo Shows Benefit in NPC Trial, Misses Statistical Significance Read Post »
Health TidingsTelix BiPASS Program Gets FDA Fast Track for Prostate Cancer Imaging Telix BiPASS Program Gets FDA Fast Track for Prostate Cancer Imaging Read Post »
Health TidingsFDA Accepts Roche’s Fenebrutinib NDA Under Priority Review for Relapsing ... FDA Accepts Roche’s Fenebrutinib NDA Under Priority Review for Relapsing ... Read Post »
Health TidingsAlmirall’s New Lebrikizumab and Tildrakizumab Data Highlight Long-Term Ou... Almirall’s New Lebrikizumab and Tildrakizumab Data Highlight Long-Term Ou... Read Post »
Health TidingsZepbound vs Wegovy HD: Tirzepatide Shows Greater Weight Loss Zepbound vs Wegovy HD: Tirzepatide Shows Greater Weight Loss Read Post »
Health TidingsZeleciment Basivarsen Shows Sustained Functional Improvement in Myotonic Dy... Zeleciment Basivarsen Shows Sustained Functional Improvement in Myotonic Dy... Read Post »
Health Tidings Medical DevicesGammaTile Shows Superior Tumor Control and Overall Survival in Phase 3 ROAD... GammaTile Shows Superior Tumor Control and Overall Survival in Phase 3 ROAD... Read Post »
Health TidingsInvivyd VYD2311 Shows Positive Phase 3 LIBERTY Results in COVID-19 Invivyd VYD2311 Shows Positive Phase 3 LIBERTY Results in COVID-19 Read Post »
Health TidingsIfezuntirgene Inilparvovec Shows 48-Month Data in Huntington’s Disease Ifezuntirgene Inilparvovec Shows 48-Month Data in Huntington’s Disease Read Post »
Health TidingsHUTCHMED, AstraZeneca Submit US NDA for ORPATHYS + TAGRISSO HUTCHMED, AstraZeneca Submit US NDA for ORPATHYS + TAGRISSO Read Post »
Health Tidings Mergers & AcquisitionsAstraZeneca Invests $2 Billion in Summit to Advance Ivonescimab-ADC Combina... AstraZeneca Invests $2 Billion in Summit to Advance Ivonescimab-ADC Combina... Read Post »
Health Tidings Mergers & AcquisitionsNovo Secures Global Rights to Hengrui’s Once-Weekly Oral GLP-1/GIP Agonis... Novo Secures Global Rights to Hengrui’s Once-Weekly Oral GLP-1/GIP Agonis... Read Post »
GenericsTeva’s DEGEVMA Receives U.S. FDA Approval as Biosimilar to Xgeva Teva’s DEGEVMA Receives U.S. FDA Approval as Biosimilar to Xgeva Read Post »
Health TidingsIfinatamab Deruxtecan BLA Withdrawn for ES-SCLC Ifinatamab Deruxtecan BLA Withdrawn for ES-SCLC Read Post »
Health Tidings Mergers & AcquisitionsMerck and SciBrunch Sign $2.13 Billion Deal for KRAS G12D Inhibitor SPR2015 Merck and SciBrunch Sign $2.13 Billion Deal for KRAS G12D Inhibitor SPR2015 Read Post »
Health TidingsTTX-MC138 Shows Sustained Disease Control in Phase 1a Trial TTX-MC138 Shows Sustained Disease Control in Phase 1a Trial Read Post »
Health TidingsFDA Grants Priority Review for Elinzanetant in Breast Cancer VMS FDA Grants Priority Review for Elinzanetant in Breast Cancer VMS Read Post »
GenericsLupin Secures U.S. FDA Tentative Approval for Apixaban Oral Suspension Lupin Secures U.S. FDA Tentative Approval for Apixaban Oral Suspension Read Post »
Health TidingsAkeso Launches Global Phase III Trial of Cadonilimab in First-Line HER2-Neg... Akeso Launches Global Phase III Trial of Cadonilimab in First-Line HER2-Neg... Read Post »
Health TidingsTipelukast Improves HDL-C and HDL-P in Phase 2 Trial, While Key Endpoints F... Tipelukast Improves HDL-C and HDL-P in Phase 2 Trial, While Key Endpoints F... Read Post »
Health TidingsInnovent and Takeda Expand Phase 3 IBI363 Program to Non-Squamous NSCLC Innovent and Takeda Expand Phase 3 IBI363 Program to Non-Squamous NSCLC Read Post »
Health TidingsZENBEXUS Shows Deeper Responses in Relapsed Multiple Myeloma ZENBEXUS Shows Deeper Responses in Relapsed Multiple Myeloma Read Post »
Health TidingsCARVYKTI Shows 5-Year Disease Control in Multiple Myeloma CARVYKTI Shows 5-Year Disease Control in Multiple Myeloma Read Post »
Health TidingsClywedog’s balomenib Shows Sustained HbA1c Reduction in Type 2 Diabetes Clywedog’s balomenib Shows Sustained HbA1c Reduction in Type 2 Diabetes Read Post »
Health TidingsGossamer Bio Files First NDA for Seralutinib in Pulmonary Arterial Hyperten... Gossamer Bio Files First NDA for Seralutinib in Pulmonary Arterial Hyperten... Read Post »
Health TidingsImfinzi Plus Enfortumab Vedotin Gets FDA Priority Review in Cisplatin-Ineli... Imfinzi Plus Enfortumab Vedotin Gets FDA Priority Review in Cisplatin-Ineli... Read Post »
Health Tidings Mergers & AcquisitionsHenlius, Amberstone Develop Tumor-Activated TCEs for Solid Tumors Henlius, Amberstone Develop Tumor-Activated TCEs for Solid Tumors Read Post »
Health Tidings Mergers & AcquisitionsAtavistik Bio, Roche Partner on Allosteric CVRM Drugs Atavistik Bio, Roche Partner on Allosteric CVRM Drugs Read Post »
Health TidingsRemlifanserin Phase 2 Trial Narrowly Misses Primary Endpoint in Alzheimers ... Remlifanserin Phase 2 Trial Narrowly Misses Primary Endpoint in Alzheimers ... Read Post »
Health TidingsMerck’s Remigromig Meets Non-Inferiority Endpoint in Phase 2b/3 DME Trial Merck’s Remigromig Meets Non-Inferiority Endpoint in Phase 2b/3 DME Trial Read Post »
Health TidingsAbsci Reports Positive Interim Phase 1 Safety and PK Data for ABS-201 in An... Absci Reports Positive Interim Phase 1 Safety and PK Data for ABS-201 in An... Read Post »
Health TidingsKasvu Raises €30 Million to Advance TrkB Neuroplastogen KTX-0141 Into Cli... Kasvu Raises €30 Million to Advance TrkB Neuroplastogen KTX-0141 Into Cli... Read Post »
Health TidingsMHRA Approves Lurbinectedin Plus Atezolizumab for Extensive-Stage Small Cel... MHRA Approves Lurbinectedin Plus Atezolizumab for Extensive-Stage Small Cel... Read Post »
Health TidingsArcturus Reports Interim Phase 2 OTC Data for ARCT-810, Advances LUNAR 2.0 Arcturus Reports Interim Phase 2 OTC Data for ARCT-810, Advances LUNAR 2.0 Read Post »
Health TidingsViferaXS Raises €12 Million to Advance CLLTAXS01 Into Phase II in CLL ViferaXS Raises €12 Million to Advance CLLTAXS01 Into Phase II in CLL Read Post »
Health TidingsFDA Updates WINREVAIR Label with HYPERION Data in Newly Diagnosed PAH FDA Updates WINREVAIR Label with HYPERION Data in Newly Diagnosed PAH Read Post »
Health TidingsACI-7104 Shows 100% Antibody Response in Phase 2 Parkinson’s Disease Tria... ACI-7104 Shows 100% Antibody Response in Phase 2 Parkinson’s Disease Tria... Read Post »
Health TidingsCBL-514 Reduces Dercum’s Disease Pain in Phase 2 Trial, Supporting Lipede... CBL-514 Reduces Dercum’s Disease Pain in Phase 2 Trial, Supporting Lipede... Read Post »
Health TidingsCelldex’s Barzolvolimab Hits Phase 3 Endpoints in Chronic Spontaneous Urt... Celldex’s Barzolvolimab Hits Phase 3 Endpoints in Chronic Spontaneous Urt... Read Post »
